FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

June 14, 2022

Topic 1: The Committee will meet in open session to discuss amending the emergency use authorization (EUA) of the Moderna COVID-19 Vaccine to include the prevention of COVID-19 in children and adolescents 6 years through 17 years of age

8:30 a.m.	**Opening Remarks: Call to Order and Welcome (5 Min)** Arnold Monto, M.D. Acting Chair, VRBPAC Emeritus Professor of Public Health and Epidemiology, University of Michigan **Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 Min)** Prabhakara Atreya, Ph.D., Director, Acting DFO, VRBPAC and Sussan Paydar, Ph.D. Alt. DFO, VRBPAC Division Scientific Advisors and Consultants, CBER, FDA
8:55 a.m.	**FDA Introduction (20 Min)** **Welcome (5 Min)** • Peter Marks, M.D. Ph.D. Director, Center for Biologics Evaluation and Research (CBER) **Introduction to Topic 1: Moderna COVID-19 Vaccine: Request for Emergency Use Authorization (EUA) Amendment, Use of a 2-Dose Primary Series in Children and Adolescents 6 years through 17 Years of Age (10 Min)** • Sudhakar Agnihothram, B. Pharm. Ph.D. Primary Reviewer Division of Vaccines and Related Products Applications (DVRPA) Office of Vaccines Research and Review (OVRR), CBER • Q& A – 5 Min

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

9:15 a.m.	**<u>Centers for Disease Control and Prevention (CDC) Presentations (55 Min)</u>** **COVID-19 Epidemiology and Disease Burden in Infants, Children and Adolescents (15 Min)** • Katherine E. Fleming-Dutra, M.D. Medical Officer COVID-19 Vaccine Policy Unit National Center for Immunization and Respiratory Diseases CDC **Update on mRNA COVID-19 Vaccine Effectiveness (15 Min)** • Ruth Link-Gelles, PH.D.M.PH. LCDR, U.S. Public Health Service COVID-19 Vaccine Effectiveness Program Lead Division of Viral Diseases, CDC **Update on mRNA COVID-19 Vaccine Post Authorization Safety Assessment in Pediatric Age Groups (15 Min)** • Tom Shimabukuro, M.D. M.PH.M.B.A. Captain, U.S. Public Health Service Director Immunization Safety Office, CDC • Q & A: 10 Min
10:10 a.m.	**<u>FDA Presentation</u>** **Safety Surveillance of COVID-19 Vaccines in Children and Adolescents (15 min)** • Hui-Lee Wong, Ph.D. Associate Director for Innovation and Development Office of Biostatistics and Pharmacovigilance (OBPV), CBER • Q & A: 5 Min

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

10:30 a.m.	**Break 10 Min**
10:40 a.m.	**<u>Sponsor Presentation: (60 Min including Q&A)</u>** **mRNA-1273 (Moderna COVID-19 Vaccine) – Request for Emergency Use Authorization in Individuals 6 - 17 Years of Age (50 Min)** • Carla Vinals, Ph.D.- Vice President, Regulatory Affairs Strategy, Infectious Diseases, ModernaTX, Inc. • Evan Anderson, M.D., FAAP - Associate Professor, Pediatrics and Medicine, Emory University School of Medicine • Jacqueline Miller, M.D., FAAP - Senior Vice President, Therapeutic Area Head, Infectious Diseases, ModernaTX, Inc. • Rituparna Das, M.D., Ph.D. - Vice President, Clinical Development, COVID-19 Vaccines, ModernaTX, Inc. • Q & A: 10 Min
11:40 a.m.	**<u>FDA presentations (60 Min including Q &A)</u>** **FDA Review of Effectiveness and Safety of Moderna COVID-19 Vaccine in Children and Adolescents 6 through 17 Years of Age (50 min)** • Rachel Zhang, M.D. Team Leader Clinical Review Staff, Immediate Office of Director DVRPA, OVRR, CBER, FDA Q & A- 10 Min
12:40 p.m.	**<u>Lunch (20 Min)</u>**

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

1:00 p.m.	**Open Public Hearing (60 Min)**
2:00 p.m.	**Additional Q & A for CDC, FDA and Sponsor Presenters (50 Min)**
2:50 p.m.	**Break (10 Min)**
3:00 p.m.	**Committee Discussion and Voting (120 Min)**
5:00 p.m.	**Meeting Adjourned - DFO**

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

June 15, 2022

Topic 2: The Committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 Vaccine to include the prevention of COVID-19 in infants and children 6 months through 5 years of age, and also to discuss amending the EUA of the Pfizer-BioNTech COVID -19 Vaccine to include the prevention of COVID-19 in infants and children 6 months through 4 years of age

Time	Presentation/Presenter
8:30 a.m.	**Opening Remarks: Call to Order and Welcome (5 Min)** Arnold Monto, M.D. Acting Chair, VRBPAC Emeritus Professor of Public Health and Epidemiology, University of Michigan **Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 Min)** Prabhakara Atreya, Ph.D., Director, Acting DFO, VRBPAC and Sussan Paydar, Ph.D. Alt. DFO, VRBPAC Division Scientific Advisors and Consultants, CBER, FDA
8:55 a.m.	**FDA Introduction (20 Min)** **Welcome (5 Min)** • Peter Marks, M.D. Ph.D. Director, Center for Biologics Evaluation and Research (CBER) **Moderna COVID-19 Vaccine: Request for Emergency Use Authorization (EUA) Amendment, use of a 2-Dose Primary Series in Infants and Children 6 Months through 5 Years of Age, and** **Pfizer-BioNTech COVID-19 Vaccine: Request for EUA Amendment, Use of a 3-Dose Primary Series in Infants and Children 6 Months through 4 Years of Age (10 Min)** • Sudhakar Agnihothram, Ph.D. and • Ramachandra Naik, Ph.D. Division of Vaccines and Related Products Applications (DVRPA), OVRR, CBER, FDA

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

	• Q & A – 5 Min
9:15 a.m.	**Sponsor Presentation: (45 Min including Q&A)** **mRNA-1273 (Moderna COVID-19 Vaccine) – Request for Emergency Use Authorization for Use in Individuals 6 Months through 5 Years of Age (35 Min)** • Carla Vinals, Ph.D.- Vice President, Regulatory Affairs Strategy, Infectious Diseases, ModernaTX, Inc. • Evan Anderson, M.D., FAAP - Associate Professor, Pediatrics and Medicine, Emory University School of Medicine • Jacqueline Miller, M.D., FAAP - Senior Vice President, Therapeutic Area Head, Infectious Diseases, ModernaTX, Inc. • Rituparna Das, M.D., Ph.D. - Vice President, Clinical Development, COVID-19 Vaccines, ModernaTX, Inc. • Q & A: 10 Min
10:00 a.m.	**FDA presentation (45 Min including Q &A)** **FDA Review of Effectiveness and Safety of Moderna COVID-19 Vaccine in Infants and Children 6 Months through 5 Years of Age (35 Min)** • Robin Wisch, M.D. Medical Officer Clinical Review Staff, Immediate Office of Director, DVRPA, OVRR, CBER, FDA • Q & A- 10 Min
10:45 a.m.	**Break (15 Min)**
11:00 a.m.	**Sponsor Presentation: (45 Min including Q&A)**

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
174th Meeting of the Vaccines and Related Biological Products Advisory Committee
Silver Spring, MD
June 14-15, 2022
AGENDA

	BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine) – Request for Emergency Use Authorization for Use in Infants and Children 6 Months through 4 Years of Age (35 Min) • William C. Gruber, MD, FAAP, FIDSA, FPIDS Senior Vice President, Vaccine Clinical Research and Development, Pfizer Inc. • Q & A: 10 Min
11:45 a.m.	**FDA presentation (45 min including Q &A)** **FDA Review of Effectiveness and Safety of Pfizer-BioNTech COVID-19 Vaccine in Infants and Children 6 Months through 4 Years of Age (35 Min)** • Susan Wollersheim, M.D. Medical Officer, Clinical Review Branch 1 DVRPA, OVRR, CBER • Q & A- 10 Min
12:30 p.m.	**Lunch (30 Min)**
1:00 p.m.	**Open Public Hearing (60 Min)**
2:00 p.m.	**Additional Q & A for FDA and Sponsor Presenters (50 Min)**
2:50 p.m.	**Break (10 Min)**
3:00 p.m.	**Committee Discussion and Voting (120 Min)**
5:00 p.m.	**Meeting Adjourned - DFO**